Amifampridine: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) recommended or restricted amifampridine, while AWMSG (Wales) and SMC (Scotland) did not recommend it.
On the same population the two systems disagree outright: PBAC (Australia) recorded recommended for “Lambert-Eaton myasthenic syndrome”, while SMC (Scotland) recorded not recommended for “Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.”.
The file has been open for more than a decade: 13.7 years separate the first record, 22 Mar 2010 at AWMSG (Wales), from the most recent, 7 Nov 2023 at PHARMAC (New Zealand).
PBAC (Australia) changed its position: not recommended in 2021, recommended by 2022, after a resubmission.
No assessment is on file from TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
2 of these 7 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess amifampridine, on 22 Mar 2010; PHARMAC (New Zealand) did not open a file until 7 Nov 2023 — an unusually long tail of 13.7 years between the earliest and latest system to look at it.
2 of the 5 agencies here assessed amifampridine more than once, PBAC (Australia) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed amifampridine.
The full ledger for amifampridine reads 3 not recommended, 2 recommended, 1 advice and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 7 Nov 2023 | Lambert Eaton Myasthenic Syndrome | funding application decided · decision reached | source |
| PBAC (Australia) | 2022 | Lambert-Eaton myasthenic syndrome | Recommended | source |
| SMC (Scotland) | 13 Aug 2012 | Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. | not recommended | source |
| HAS (France) | 2 Jun 2010 | Listing (Transparency Committee) | ASMR IV | source |
| AWMSG (Wales) | 22 Mar 2010 | Symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) | not endorsed (non-submission) | source |
2 further decisions for amifampridine, across 2 agencies, are not shown here.
Related molecules
- tafamidis — same ATC class N07X — Other nervous system
- vutrisiran — same ATC class N07X — Other nervous system
- pitolisant — same ATC class N07X — Other nervous system
- fampridine — same ATC class N07X — Other nervous system
- omaveloxolone — same ATC class N07X — Other nervous system
- patisiran — same ATC class N07X — Other nervous system
Coverage: 7 decisions for amifampridine from 5 agencies, 2010 to 2023. Data to 7 Sep 2026. ATC class N07X — Other nervous system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.